RecruitingPhase 2NCT06756269

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

A Randomised, Double-blind, Placebo and Positive Controlled, Phase 2 Clinical Trial to Evaluate the Safety and Immunogenicity of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 9-45 Years

Sponsor

Shanghai Bovax Biotechnology Co., Ltd.

Enrollment

330 participants

Start Date

Jan 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.

Eligibility

Min Age: 9 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called 9-HPV vaccine, a biological treatment called High dose for 15-HPV vaccine, and others for people with genital wart, hpv infection, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 9 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMedium dose for 15-HPV vaccine

Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

BIOLOGICALHigh dose for 15-HPV vaccine

Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

BIOLOGICALPlacebo

Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

BIOLOGICAL9-HPV vaccine

Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule